Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Uterine Cervical Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Spondylarthritis 1 Precancerous Conditions 1 Papillomavirus Infections 1 Neuroblastoma 1 Neoplasms by Site 1 Myelodysplastic Syndromes 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Genital Neoplasms, Female 1 Genital Diseases, Female 1 Genital Diseases 1 Female Urogenital Diseases and Pregnancy Complications 1

Interventions

Carboplatin 340 Cisplatin 238 Paclitaxel 203 Radiotherapy 195 Pemetrexed 187 Docetaxel 169 Gemcitabine 157 pembrolizumab 141 Erlotinib Hydrochloride 107 Etoposide 99 Magnetic Resonance Spectroscopy 93 Bevacizumab 91 Specimen Handling 76 Nivolumab 73 Radiosurgery 72 durvalumab 69 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 49 atezolizumab 42 Irinotecan 42 Radiation 40 Topotecan 39 Biopsy 39 Standard of Care 38 Cyclophosphamide 38 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Pregnancy Tests × Clear all

NCT06620835 2026-04-29

OPTALK

Groupe Francais De Pneumo-Cancerologie

Phase 2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡